Assessing the Risk of HCC for Hepatitis B Treatments - MD Magazine

Tenofovir was linked to a decreased incidence rate of HCC compared to entecavir. However, this difference was not considered statistically significant.

New research shows very little difference in the risk of hepatocellular carcinoma (HCC) for patients with chronic hepatitis B virus (HBV) treated with tenofovir compared to patients treated with ente… [+3272 chars]

full article...